These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells. Egele K; Samaddar S; Schneider N; Thompson D; Wenz G J Mater Chem B; 2019 Jan; 7(4):528-537. PubMed ID: 31372225 [TBL] [Abstract][Full Text] [Related]
9. Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice. Fukaura M; Ishitsuka Y; Shirakawa S; Ushihama N; Yamada Y; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Higaki K; Matsuo M; Irie T Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466390 [TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease. Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436 [TBL] [Abstract][Full Text] [Related]
11. [Inclusion Solves Insolubility -Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C]. Irie T Yakugaku Zasshi; 2022; 142(4):389-400. PubMed ID: 35370195 [TBL] [Abstract][Full Text] [Related]
12. Normalization of cholesterol homeostasis by 2-hydroxypropyl-β-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice. Peake KB; Vance JE J Biol Chem; 2012 Mar; 287(12):9290-8. PubMed ID: 22277650 [TBL] [Abstract][Full Text] [Related]
13. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C. Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944 [TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C. Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767 [TBL] [Abstract][Full Text] [Related]
15. Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function. Lopez AM; Terpack SJ; Posey KS; Liu B; Ramirez CM; Turley SD Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):780-7. PubMed ID: 25115571 [TBL] [Abstract][Full Text] [Related]
16. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Vite CH; Bagel JH; Swain GP; Prociuk M; Sikora TU; Stein VM; O'Donnell P; Ruane T; Ward S; Crooks A; Li S; Mauldin E; Stellar S; De Meulder M; Kao ML; Ory DS; Davidson C; Vanier MT; Walkley SU Sci Transl Med; 2015 Feb; 7(276):276ra26. PubMed ID: 25717099 [TBL] [Abstract][Full Text] [Related]
17. Cyclodextrins applied to the treatment of lysosomal storage disorders. Ishitsuka Y; Irie T; Matsuo M Adv Drug Deliv Rev; 2022 Dec; 191():114617. PubMed ID: 36356931 [TBL] [Abstract][Full Text] [Related]
18. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial. Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795 [TBL] [Abstract][Full Text] [Related]
19. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial. Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901 [TBL] [Abstract][Full Text] [Related]
20. Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. Nicoli ER; Al Eisa N; Cluzeau CV; Wassif CA; Gray J; Burkert KR; Smith DA; Morris L; Cologna SM; Peer CJ; Sissung TM; Uscatu CD; Figg WD; Pavan WJ; Vite CH; Porter FD; Platt FM PLoS One; 2016; 11(3):e0152007. PubMed ID: 27019000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]